Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 5/20 | 0.68 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | KLK7 | P49862 | 1/20 | 0.56 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6384850 | 1.00 | PREP (0.68) | PREPCTRB1NPSR1TSHRL3MBTL1 | |
| SCHEMBL488745 | 1.00 | PREP (0.68) | PREPCTRB1NPSR1TSHRL3MBTL1 | |
| SCHEMBL8161155 | 0.99 | PREP (0.67) | PREPCTRB1NPSR1TSHRL3MBTL1 | |
| SCHEMBL8161153 | 0.99 | PREP (0.67) | PREPCTRB1NPSR1TSHRL3MBTL1 | |
| SCHEMBL8161156 | 0.99 | PREP (0.67) | PREPCTRB1NPSR1TSHRL3MBTL1 | |
| SCHEMBL10556342 | 0.97 | PREP (0.65) | PREPCTRB1NPSR1 | |
| SCHEMBL8750859 | 0.97 | PREP (0.68) | PREPCTRB1NPSR1TSHRL3MBTL1 | |
| SCHEMBL8750854 | 0.97 | PREP (0.68) | PREPCTRB1NPSR1TSHRL3MBTL1 | |
| SCHEMBL8750947 | 0.97 | PREP (0.68) | PREPCTRB1NPSR1TSHRL3MBTL1 | |
| SCHEMBL4274494 | 0.96 | PREP (0.64) | PREPCTRB1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1603570-B9 | AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | SUGEN INC (US) | 2013-10-23 | — | — | EP | disclosed |
| EP-1603570-B1 | AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | SUGEN INC (US) | 2013-01-23 | — | — | EP | disclosed |
| EP-2476667-A2 | Aminoheteroaryl compounds as protein kinase inhibitors | Sugen, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| US-8106197-B2 | Aminoheteroaryl compounds as protein kinase inhibitors | PFIZER INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-8106197-B2 | Aminoheteroaryl compounds as protein kinase inhibitors | PFIZER INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-8106197-B2 | Aminoheteroaryl compounds as protein kinase inhibitors | PFIZER INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-7230098-B2 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | SUGEN, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-7230098-B2 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | SUGEN, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-20070072874-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | SUGEN, INC. | 2007-03-29 | — | — | US | disclosed |
| US-20070072874-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | SUGEN, INC. | 2007-03-29 | — | — | US | disclosed |
| EP-1434774-A1 | 3-(4-SUBSTITUTED HETEROCYCLYL)-PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Sugen, Inc. (US) | 2004-07-07 | — | — | EP | disclosed |
| US-6642232-B2 | Antitumor agents | SUGEN, INC. | 2003-11-04 | — | — | US | disclosed |
| US-6599902-B2 | For treating or preventing a protein kinase related disorder | SUGEN, INC. | 2003-07-29 | — | — | US | disclosed |
| US-20030130235-A1 | 3-[4-Substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2- indolinone derivatives as kinase inhibitors | SUGEN, INC. | 2003-07-10 | — | — | US | disclosed |
| US-20030130280-A1 | Treatment of acute myeloid leukemia with indolinone compounds | SUGEN, INC. | 2003-07-10 | — | — | US | disclosed |
| US-20030125370-A1 | 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | SUGEN, INC. | 2003-07-03 | — | — | US | disclosed |
| WO-2003031438-A1 | 3-[4-(SUBSTITUTED HETEROCYCLYL)-PYRROL-2-YLMETHYLIDENE]-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | SUGEN, INC. (US) | 2003-04-17 | — | — | WO | disclosed |
| WO-2002096361-A2 | 5-ARALKYLSULFONYL-3- (PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | SUGEN, INC. (US) | 2002-12-05 | — | — | WO | disclosed |
| US-6017929-A | Cholinesterase activator | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2000-01-25 | — | — | US | disclosed |
| EP-0754454-A1 | CHOLINESTERASE ACTIVATOR | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1997-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130280-A1 | Treatment of acute myeloid leukemia with indolinone compounds | FLT3, FLI1, MCL1 | PREP 3685/4885CTRB1 4750/4885NPSR1 3427/4885 |
| US-20030130235-A1 | 3-[4-Substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2- indolinone derivatives as kinase inhibitors | PDGFRB, PDGFRA, KDR | PREP 2082/4885CTRB1 4037/4885NPSR1 2114/4885 |
| US-20070072874-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | MET, MAP4K1, MAP4K2 | PREP 3469/4885CTRB1 4595/4885NPSR1 3095/4885 |
| US-20030125370-A1 | 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | DMPK, ADK, MAP3K20 | PREP 3215/4885CTRB1 4423/4885NPSR1 2345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.